Evidence map›Paper›PMID 34006287›Full record

Observational studyJournal of orthopaedic surgery and research2021

Association between intravenous iron therapy and short-term mortality risk in older patients undergoing hip fracture surgery: an observational study.

Silas Zacharias Clemmensen, Kristian H Kragholm, Dorte Melgaard, Lene T Hansen, Johannes Riis, Christian Cavallius, Marianne M Mørch, Maria Lukács Krogager

Registry-linked trialOpen access · goldAbstract readObservational Study
In one paragraph

Observational study in Journal of orthopaedic surgery and research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06080893 (The Effect of Preoperative Ferric Carboxymaltose Administration on Mortality in Geriatric Hip Fractures), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06080893 phase4completednot on this mapstarted 2023, after this paper: background citation

The Effect of Preoperative Ferric Carboxymaltose Administration on Mortality in Geriatric Hip Fractures

TypeinterventionalSponsorIstanbul UniversityRan2023 to 2025Enrolled209ConditionsHip Fractures, Anemia, Complication,PostoperativeArmsFerric carboxymaltose
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Observational
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Silas Zacharias ClemmensenCenter for Clinical Research, North Denmark Regional Hospital, Hjørring, Denmark. silas.clemmensen@rn.dk.ORCID http://orcid.org/0000-0002-4245-0443
Kristian H KragholmCenter for Clinical Research, North Denmark Regional Hospital, Hjørring, Denmark.
Dorte MelgaardCenter for Clinical Research, North Denmark Regional Hospital, Hjørring, Denmark.
Lene T HansenDepartment of Geriatric Medicine, North Denmark Regional Hospital, Hjørring, Denmark.
Johannes RiisCenter for Clinical Research, North Denmark Regional Hospital, Hjørring, Denmark.
Christian CavalliusDepartment of Orthopedic Surgery, Aalborg University Hospital, Hjørring, Denmark.
Marianne M MørchDepartment of Geriatric Medicine, North Denmark Regional Hospital, Hjørring, Denmark.
Maria Lukács KrogagerDepartment of Cardiology, Aalborg University Hospital, Aalborg, Denmark.
Aalborg University Hospital · DKNorth Denmark Region · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAnemia is common among ortho-geriatric hip fracture patients and is associated with prolonged recovery and increased postoperative mortality rate. Intravenous iron seems to increase hemoglobin recovery and reduce the mortality rate in patients undergoing orthopedic surgeries. This study investigated the association between short-term mortality risk and intravenous iron therapy in older patients undergoing hip fracture surgery.

methodsThis observational study included 210 patients undergoing hip fracture surgery from July 2018 to May 2020. These 210 patients were alive and had a hemoglobin ≤ 6.5 mmol/L on the 3rd postoperative day. In May 2019, a local intravenous iron therapy protocol was implemented and recommended intravenous iron (Monofer©) if hemoglobin on the 3rd postoperative day was ≤ 6.5 mmol/L. According to the treatment of postoperative anemia between the 1st and 3rd day post-surgery, the patients were divided into four groups: no treatment (n=52), blood transfusion (n=38), IV Monofer (n=80), and blood transfusion and IV Monofer (n=40). Primary outcome was 30-day mortality post-surgery. The secondary outcome was the impact on hemoglobin level 14-30 days postoperatively. Multivariable Cox regression was used to estimate the 30-day mortality standardized for covariates.

resultsOf 210 patients, 17 (8.1%) died within 30 days after surgery. There was a significantly lower mortality among the patients who received IV Monofer compared to those who received no treatment (HR 0.17, 95% CI [0.03-0.93], P = 0.041). Among the 86 patients with available hemoglobin measurements within 14 to 30 days post-surgery, there was no significant difference in hemoglobin level between the various treatment groups (mean 6.6 mmol/L, P = 0.1165).

conclusionIV Monofer on the 3rd postoperative day in older hip fracture patients seemed to reduce 30-day mortality compared with no treatment. No significant differences in hemoglobin levels between 14 and 30 days post-surgery across treatment groups were found, although this was assessed in a subset of patients with available hemoglobin levels warranting further study.

Indexed as

Administration, IntravenousAgedAged, 80 and overAnemiaDisaccharidesFemaleFerric CompoundsHemoglobinsHip FracturesHumansMalePostoperative PeriodDisaccharidesFerric CompoundsHemoglobinsiron isomaltoside 1000AnemiaHip fracturesIronMortalityOlder people

Identifiers

PMID34006287
PMCPMC8130414
OpenAlexW3160040246

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.